GHM ToRCH IgG Combo Rapid Test US – Comprehensive Qualitative Detection of IgG Antibodies to Toxoplasma gondii, Rubella Virus, Cytomegalovirus, and Herpes Simplex Virus 1/2 with 15-Minute Results

SKU: GHM ToRCH IgG Combo Rapid Test US
Brand: Global Healthcare Medical

Product Overview

Global Healthcare Medical GHM ToRCH IgG Combo Rapid Test US is a lateral flow chromatographic immunoassay designed for the qualitative detection of IgG antibodies to Toxoplasma gondii (Toxo), Rubella virus (Rubella), Cytomegalovirus (CMV), and Herpes simplex virus 1/2 (HSV 1/2) in human whole blood, serum, or plasma specimens. The kit is intended for use by healthcare professionals as a screening test and as an aid in the diagnosis of ToRCH infections.

ToRCH is an acronym for a group of infectious agents—Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV), and Herpes simplex virus (HSV)—that can cause severe congenital infections when transmitted from mother to fetus during pregnancy. These infections are a leading cause of birth defects worldwide and remain a significant public health concern. ToRCH screening is recommended to determine the basic immune status of women preparing for pregnancy and to assess infection status. Serological screening for TORCH infections is an effective method for preventing congenital infections caused by ToRCH pathogens.

The clinical significance of ToRCH screening lies in the fact that most primary infections during pregnancy are asymptomatic or present with non-specific symptoms, making laboratory detection essential for identifying women at risk. Primary infection with any of these pathogens during pregnancy—particularly in the first trimester—poses the greatest risk of vertical transmission and fetal harm. The GHM ToRCH IgG Combo Rapid Test US provides a comprehensive, point-of-care solution for the simultaneous detection of IgG antibodies to all four ToRCH pathogens from a single patient sample, enabling timely clinical decision-making and supporting appropriate patient management.

The GHM ToRCH IgG Combo Rapid Test US delivers qualitative results in 15 minutes, supporting rapid clinical decision-making at the point of care. The test is compatible with whole blood (venipuncture or fingerstick), serum, and plasma specimens, providing flexible sample collection options suitable for a wide range of clinical settings, including obstetric clinics, prenatal screening programs, infectious disease clinics, and clinical laboratories.

The kit is intended for in vitro diagnostic use and professional use only, suitable for application scenarios including obstetric clinics, prenatal screening programs, infectious disease clinics, hospital laboratories, and clinical laboratories. The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system covering in vitro diagnostic test kits and analyzers based on immunochromatography.

Key Features & Benefits

4-in-1 Combo Detection – ToRCH Panel in One Test

The GHM ToRCH IgG Combo Rapid Test US utilizes a lateral flow chromatographic immunoassay capable of simultaneously detecting IgG antibodies to all four ToRCH pathogens—Toxoplasma gondii, Rubella virus, Cytomegalovirus, and Herpes simplex virus 1/2—from a single patient sample. This comprehensive panel design reduces the need for multiple specimen collections and separate testing procedures, streamlining the screening workflow and supporting efficient, integrated ToRCH screening programs.

Fast Results – 15 Minutes

The GHM ToRCH IgG Combo Rapid Test US provides qualitative results in 15 minutes, supporting rapid clinical decision-making and efficient patient workflow in point-of-care settings. Rapid results enable immediate clinical assessment, which is particularly valuable in prenatal screening settings where timely identification of seronegative women allows for appropriate preventive counseling and serological monitoring during pregnancy.

Whole Blood / Serum / Plasma Compatibility – Flexible Sample Collection

The GHM ToRCH IgG Combo Rapid Test US is compatible with whole blood (venipuncture or fingerstick), serum, and plasma specimens, providing flexible sample collection options to accommodate different clinical protocols and patient needs. The test requires only a small sample volume, making it suitable for both clinic-based and field-based testing scenarios.

Clinical Utility – Aid for Diagnosis of ToRCH Infections and Immunity Assessment

The GHM ToRCH IgG Combo Rapid Test US is intended for use as a screening test and as an aid in the diagnosis of ToRCH infections and immunity assessment. The test provides rapid serological diagnosis, enabling timely clinical decision-making and supporting patient management.

The IgG antibody response to ToRCH pathogens provides valuable information about past exposure and immune status. Detection of specific IgG antibodies indicates past infection or vaccination, suggesting immunity to the respective pathogen. ToRCH screening before pregnancy is recommended to determine the basic immune status of women preparing for pregnancy. A positive IgG result for Rubella virus, for example, indicates immunity and generally does not affect pregnancy planning or fetal health. For Toxoplasma gondii, CMV, and HSV, positive IgG results indicate past exposure, while seronegative women require preventive counseling and monitoring during pregnancy to reduce the risk of primary infection.

The test is particularly valuable in prenatal screening programs, where determining maternal serostatus is essential for identifying seronegative women who require preventive counseling and serological monitoring during pregnancy. The test is also suitable for use in decentralized testing environments where laboratory infrastructure may be limited.

High Accuracy – Trusted Clinical Performance

The GHM ToRCH IgG Combo Rapid Test US is designed to deliver reliable clinical performance with high sensitivity and specificity across all four ToRCH pathogen targets. A similar assay evaluated in infertile women of childbearing age reported excellent seroprevalence correlation with reference methods. In a study of 17,807 women, the overall IgG seroprevalences of TOX, RV, CMV, HSV-1, and HSV-2 were 3.4%, 84.93%, 97.54%, 82.83%, and 10.04%, respectively, consistent with established epidemiological data. Studies of ToRCH IgG combo rapid tests have reported excellent agreement with ELISA and chemiluminescence immunoassay reference methods, with sensitivities and specificities suitable for routine screening applications.

Performance characteristics based on published evaluations of ToRCH antibody rapid tests. A study of ToRCH seroprevalence in 17,807 infertile women of childbearing age reported IgG seroprevalences of 3.4% for Toxoplasma gondii, 84.93% for Rubella virus, 97.54% for CMV, 82.83% for HSV-1, and 10.04% for HSV-2. Global seroprevalence studies have reported overall IgG seroprevalence rates of 20.1% for T. gondii, 91.3% for RUBV, 70.5% for CMV, 66.8% for HSV-1, and 3.5% for HSV-2 in childbearing-aged women. Detection is optimal in specimens collected and processed according to the manufacturer's instructions, and the test is best suited for use as an aid in the diagnosis of ToRCH infections and for immunity assessment. The test provides a preliminary result; confirmatory testing with reference laboratory methods and IgG avidity testing (when indicated) is recommended.

ISO 13485 Certified – Quality and Safety Compliance

The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system, demonstrating compliance with stringent international standards for the design, development, manufacture, and distribution of in vitro diagnostic test kits and analyzers.

CE Marked – European Conformity

The GHM ToRCH IgG Combo Rapid Test US is CE marked for professional in vitro diagnostic use, demonstrating conformity with applicable European regulatory requirements for diagnostic medical devices.

Product Specifications

Important Testing Notes:

• Allow the test kit and sample to reach room temperature (18–30°C) prior to testing.

• For fingerstick whole blood, clean the fingertip with an alcohol swab and allow it to dry; collect blood using a sterile lancet.

• Any visible shade of color in a Test line indicates a positive result, as intensity varies with antibody concentration.

• A negative result does not rule out ToRCH infection, particularly during the early acute phase of infection before antibodies become detectable, or in immunocompromised patients who may have impaired antibody responses.

• A positive IgG result indicates past infection or vaccination, suggesting immunity.

• In pregnant women with both IgG and IgM positive (if IgM testing is performed separately), IgG avidity testing should be requested to further evaluate the timing of infection.

• Confirmatory testing at a reference laboratory with expertise in ToRCH diagnosis is recommended for any reactive specimen before clinical intervention.

• The U.S. Preventive Services Task Force and ACOG do not recommend routine ToRCH screening for all pregnant women; testing should be performed based on clinical judgment and individual risk assessment.

Why Clinical Professionals Choose Global Healthcare Medical

About Global Healthcare Medical

Global Healthcare Medical is dedicated to connecting healthcare providers, retailers, and distributors with high-quality medical devices designed for reliable performance. The GHM ToRCH IgG Combo Rapid Test US is part of our professional diagnostic line, developed to support accurate, efficient, and accessible point-of-care testing in clinical environments.

Our focus is on dependable performance, clear documentation, and responsive support for professional healthcare settings.